- Home
- RLGT vs ENGN Comparison
RLGT vs ENGN Comparison
Compare RLGT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLGT | ENGN |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.6M | 605.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RLGT | ENGN |
|---|---|---|
| Price | $6.63 | $8.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $8.00 | ★ $22.71 |
| AVG Volume (30 Days) | 165.2K | ★ 236.5K |
| Earning Date | 02-09-2026 | 12-22-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.35 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $925,786,000.00 | N/A |
| Revenue This Year | $3.77 | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | $21.71 | ★ N/A |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $5.44 | $2.65 |
| 52 Week High | $7.94 | $11.14 |
Technical Indicators
Market Signals| Indicator | RLGT | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 51.06 |
| Support Level | $6.28 | $8.17 |
| Resistance Level | $6.75 | $9.81 |
| Average True Range (ATR) | 0.17 | 0.68 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 55.36 | 39.72 |
Price Performance
Historical ComparisonAbout RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.